Dana Bielopolski1,2, Gilad Libresco3, Noam Barda4,5,6, Noa Dagan3,5,6,7, Tali Steinmetz1,2, Dafna Yahav2,8, David M Charytan9, Ran D Balicer3,7,10, Benaya Rozen-Zvi1,2. 1. Department of Nephrology and Hypertension, Rabin Medical Center, Petah-Tikva, Israel. 2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3. Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel. 4. ARC Innovation Center, Sheba Medical Center, Ramat-Gan, Israel. 5. Department of Software and Information Systems Engineering, Ben Gurion University, Be'er Sheva, Israel. 6. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. 7. Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute, Ramat-Gan , Israel. 8. Infectious Diseases Unit, Rabin Medical Center, Petah-Tikva, Israel. 9. Nephrology Division, New York University Langone Medical Center and Grossman School of Medicine, New York, NY, USA. 10. School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Abstract
Background: Chronic kidney disease (CKD) is a risk factor for severe coronavirus disease 2019 (COVID-19). We aimed to evaluate the real-life effectiveness of the BNT162b2 messenger RNA vaccine for a range of outcomes in patients with CKD compared with matched controls. Methods: Data from Israel's largest healthcare organization were retrospectively used. Vaccinated CKD [estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2] and maintenance dialysis patients were matched to vaccinated controls without CKD (eGFR ≥60 ml/min/1.73 m2) according to demographic and clinical characteristics. Study outcomes included documented infection with severe acute respiratory syndrome coronavirus 2, symptomatic infection, COVID-19-related hospitalization, severe disease and death. Vaccine effectiveness was estimated as the risk ratio (RR) at days 7-28 following the second vaccine dose, using the Kaplan-Meier estimator. Effectiveness measures were also evaluated separately for various stages of CKD. Results: There were 67 861 CKD patients not treated with dialysis, 2606 hemodialysis (HD) patients and 70 467 matched controls. The risk of severe disease {RR 1.84 [95% confidence interval (CI) 0.95-2.67]} and death [RR 2.00 (95% CI 0.99-5.20)] was increased in nondialysis CKD patients compared with controls without CKD following vaccination. For the subgroup of patients with eGFR <30 ml/min/1.73 m2, the risk of severe disease and death was increased compared with controls [RR 6.42 (95% CI 1.85-17.51) and RR 8.81 (95% CI 1.63-13.81), respectively]. The risks for all study outcomes were increased in HD patients compared with controls. Conclusion: Two doses of the BNT162b2 vaccine were found to be less efficient for patients with eGFR <30 ml/min/1.73 m2. Risk in HD patients is increased for all outcomes. These results suggest prioritizing patients with eGFR <30 ml/min/1.73 m2 for booster shots, pre- and post-exposure prophylaxis and early COVID-19 therapy.
Background: Chronic kidney disease (CKD) is a risk factor for severe coronavirus disease 2019 (COVID-19). We aimed to evaluate the real-life effectiveness of the BNT162b2 messenger RNA vaccine for a range of outcomes in patients with CKD compared with matched controls. Methods: Data from Israel's largest healthcare organization were retrospectively used. Vaccinated CKD [estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2] and maintenance dialysis patients were matched to vaccinated controls without CKD (eGFR ≥60 ml/min/1.73 m2) according to demographic and clinical characteristics. Study outcomes included documented infection with severe acute respiratory syndrome coronavirus 2, symptomatic infection, COVID-19-related hospitalization, severe disease and death. Vaccine effectiveness was estimated as the risk ratio (RR) at days 7-28 following the second vaccine dose, using the Kaplan-Meier estimator. Effectiveness measures were also evaluated separately for various stages of CKD. Results: There were 67 861 CKD patients not treated with dialysis, 2606 hemodialysis (HD) patients and 70 467 matched controls. The risk of severe disease {RR 1.84 [95% confidence interval (CI) 0.95-2.67]} and death [RR 2.00 (95% CI 0.99-5.20)] was increased in nondialysis CKD patients compared with controls without CKD following vaccination. For the subgroup of patients with eGFR <30 ml/min/1.73 m2, the risk of severe disease and death was increased compared with controls [RR 6.42 (95% CI 1.85-17.51) and RR 8.81 (95% CI 1.63-13.81), respectively]. The risks for all study outcomes were increased in HD patients compared with controls. Conclusion: Two doses of the BNT162b2 vaccine were found to be less efficient for patients with eGFR <30 ml/min/1.73 m2. Risk in HD patients is increased for all outcomes. These results suggest prioritizing patients with eGFR <30 ml/min/1.73 m2 for booster shots, pre- and post-exposure prophylaxis and early COVID-19 therapy.
Authors: Daniela Frasca; Alain Diaz; Maria Romero; Nicholas V Mendez; Ana Marie Landin; John G Ryan; Bonnie B Blomberg Journal: Vaccine Date: 2013-05-25 Impact factor: 3.641
Authors: Claudius Speer; Daniel Göth; Louise Benning; Mirabel Buylaert; Matthias Schaier; Julia Grenz; Christian Nusshag; Florian Kälble; Martin Kreysing; Paula Reichel; Maximilian Töllner; Asa Hidmark; Gerald Ponath; Paul Schnitzler; Martin Zeier; Caner Süsal; Christian Morath; Katrin Klein Journal: Clin J Am Soc Nephrol Date: 2021-05-24 Impact factor: 10.614
Authors: Eric D Weinhandl; James B Wetmore; Yi Peng; Jiannong Liu; David T Gilbertson; Kirsten L Johansen Journal: J Am Soc Nephrol Date: 2021-04-08 Impact factor: 14.978
Authors: Noa Dagan; Noam Barda; Eldad Kepten; Oren Miron; Shay Perchik; Mark A Katz; Miguel A Hernán; Marc Lipsitch; Ben Reis; Ran D Balicer Journal: N Engl J Med Date: 2021-02-24 Impact factor: 91.245
Authors: Sam Kant; Steven P Menez; Mohamed Hanouneh; Derek M Fine; Deidra C Crews; Daniel C Brennan; C John Sperati; Bernard G Jaar Journal: BMC Nephrol Date: 2020-10-27 Impact factor: 2.388